Randy R. Miller

Design and Pharmacology of <i>N</i>-[(3<i>R</i>)-1,2,3,4-Tetrahydroisoquinolinium- 3-ylcarbonyl]-(1<i>R</i>)-1-(4-chlorobenzyl)- 2-[4-cyclohexyl-4-(1<i>H</i>-1,2,4-triazol- 1-ylmethyl)piperidin-1-yl]-2-oxoethylamine (<b>1</b>), a Potent, Selective, Melanocortin Subtype-4 Receptor Agonist

Iyassu K. Sebhat, William J. Martin, Zhixiong Ye et al. · Journal of Medicinal Chemistry · 2002 · 190 citations · Full text

Erectile Dysfunction, Food Intake, Peptide Science +21

Integrating the Impact of Lipophilicity on Potency and Pharmacokinetic Parameters Enables the Use of Diverse Chemical Space during Small Molecule Drug Optimization

Randy R. Miller, Maria Madeira, Harold B. Wood et al. · Journal of Medicinal Chemistry · 2020 · 119 citations

Discovery of Vibegron: A Potent and Selective β₃Adrenergic Receptor Agonist for the Treatment of Overactive Bladder

Scott D. Edmondson, Cheng Zhu, Nam Fung Kar et al. · Journal of Medicinal Chemistry · 2015 · 101 citations · Full text

Regulation of Energy Homeostasis by Bombesin Receptor Subtype-3: Selective Receptor Agonists for the Treatment of Obesity

Xiao-Ming Guan, Howard Chen, Peter H. Dobbelaar et al. · Cell Metabolism · 2010 · 87 citations · Full text

Obesity, Metabolic Syndrome, Energy Homeostasis +11

Quality Improvement Initiative to Reduce the Necrotizing Enterocolitis Rate in Premature Infants

María Talavera, G. Michael Bixler, C Cozzi et al. · PEDIATRICS · 2016 · 75 citations · Full text